REV: Responsibly and reliably powering industry
With a focus on the creation of innovative technology and forward-thinking practical solutions, REV offers flexible, durable, reliable
Kramer Mazda: The largest Mazda dealership in Western Canada
The largest Mazda dealership in Calgary and Western Canada, for over 40 years Kramer Mazda has been developing
German-Canadian Care Home: An innovative new vision for elder care
Providing compassionate care to seniors in Vancouver for over 50 years, the German-Canadian Care Home is part of
Hinton Scaffold Solutions: Utilizing innovate technologies to create safer worksites
With many years of experience in the heavy industrial scaffold industry, Ontario-based Hinton Scaffold Solutions provides highly innovative
Alberta Veterinary Laboratories / Solvet: Supporting Canada’s food
Founded in 2009, Western Canadian family-owned pharmaceutical manufacturer Alberta Veterinary Laboratories manufactures and provides efficacious and cost-effective animal
Sodexo Canada: The global leader who believes the difference a day makes
Founded in Marseille in 1966, and now operating in 53 countries, Sodexo provides facilities services that drive positive
Barclay Restorations DKI: The longest running insurance restoration company in Greater Vancouver
Locally owned-and operated and serving Metro Vancouver and the Fraser Valley, Barclay Restorations DKI is a full-service restoration
CDW Canada: Helping small businesses use IT security to prepare, defend, and respond
Established in 2003, CDW Canada is a leading provider of technology solutions for business, government, education, and healthcare,
Taiwan: key to win-win approach for Canadian Industry
Taiwan’s innovation leadership and significant economic potential in Asia is an opportunity for Canada to stay competitive on
Taking charitable giving to the next level
Empowering employees to support the causes that matter most to them is the best way to maximize charitable
Lots of money seeking company acquisitions – The case of private equity
At this time, there is more money in the system than anyone can imagine. It is estimated that
There’s optimism amid instability in the Canadian construction landscape
The last year has been among the most expensive on record for many Canadians. Families and those on
Washed up elites need to stop lecturing the people
The ramblings of ex-Prime Ministers, Presidents and CEOs is a feature of all political life, history and cultures.
The political timing of Finland’s admission into NATO
It has been a few weeks since the world watched the proverbial ink of approval dry on Finland’s
How to manage the stress of making the right business decisions
It can be stressful when you have to make important decisions regarding your business. We all want to
Reclaiming Canada’s key service export: Tourism
Tourism is an increasingly dynamic sector of the global economy; pre-2019 tourism was a $1.4 trillion industry generating
Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer
Astellas Pharma Inc. (TSE: 4503, President and
CEO: Yoshihiko Hatanaka, “Astellas”) and Pfizer Inc. (NYSE: PFE) has announced the
amendment of the protocol for the registrational PROSPER trial, a multi-national, randomized,
double-blind, placebo-controlled study evaluating the efficacy and safety of XTANDI
(enzalutamide) in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer
(CRPC). The primary endpoint remains the same: metastasis-free survival (MFS). The main
purpose of the amendment is to revise the plan for the analyses of the primary and several
secondary endpoints, which allows for a reduction in the target sample size to approximately
1,440, from 1,560 patients. The companies now anticipate PROSPER top-line results will be
disclosed later this year. Previously the expected primary completion date for PROSPER was
June 2019.
“XTANDI is already a standard of care for men worldwide fighting metastatic castrationresistant
prostate cancer, but we are continually looking to evaluate this medicine for men
facing earlier stage disease,” said Steven Benner, M.D., senior vice president and global
therapeutic area head, oncology development, Astellas. “By amending the protocol for
PROSPER, we hope to be able to accelerate the evaluation of the data in this area of medical
need.”
“PROSPER is one of a number of large, randomized trials in our robust, registration-focused
development program, where we are evaluating enzalutamide in different prostate cancer
populations, including men with earlier stages of the disease,” said Mace Rothenberg, MD,
chief development officer, Oncology, Pfizer Global Product Development. “We look forward to
2
building upon the extensive body of clinical evidence that has been generated over the past
five years and established XTANDI as a standard of care for men with metastatic CRPC.”
XTANDI is approved by the U.S. Food and Drug Administration for the treatment of patients
with metastatic CRPC, based on clinical studies showing statistically significant overall
survival benefit versus placebo.
Details regarding the protocol amendment for PROSPER (NCT02003924) will be available on
ClinicalTrials.gov.
- Read the current edition
- Recent posts
